CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Ticagrelor With or Without Aspirin After Complex PCI Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) DAPT, Our Genome and Clopidogrel
|<<... 5 6 7 8 9 10 11 ...>>|

Review Article2020 Jul 1;9(7):E2064.

JOURNAL：J Clin Med . Article Link

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

G Tersalvi, L Biasco, GM Cioffi et al. Keywords: P2Y12 inhibition; acute coronary syndrome; bleeding; clopidogrel; dual antiplatelet therapy; high bleeding risk; prasugrel; tailored therapy; ticagrelor

Full Text PDF

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top